Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 15 |
List of Tables | 14 | 2 |
List of Figures | 16 | 1 |
Introduction | 17 | 1 |
Global Markets Direct Report Coverage | 17 | 1 |
Ebolavirus Infections (Ebola Hemorrhagic Fever) Overview | 18 | 1 |
Therapeutics Development | 19 | 2 |
Pipeline Products for Ebolavirus Infections (Ebola Hemorrhagic Fever) Overview | 19 | 1 |
Pipeline Products for Ebolavirus Infections (Ebola Hemorrhagic Fever) Comparative Analysis | 20 | 1 |
Ebolavirus Infections (Ebola Hemorrhagic Fever) Therapeutics under Development by Companies | 21 | 4 |
Ebolavirus Infections (Ebola Hemorrhagic Fever) Therapeutics under Investigation by Universities/Institutes | 25 | 1 |
Ebolavirus Infections (Ebola Hemorrhagic Fever) Pipeline Products Glance | 26 | 4 |
Late Stage Products | 26 | 1 |
Clinical Stage Products | 27 | 1 |
Early Stage Products | 28 | 1 |
Unknown Stage Products | 29 | 1 |
Ebolavirus Infections (Ebola Hemorrhagic Fever) Products under Development by Companies | 30 | 5 |
Ebolavirus Infections (Ebola Hemorrhagic Fever) Products under Investigation by Universities/Institutes | 35 | 1 |
Ebolavirus Infections (Ebola Hemorrhagic Fever) Companies Involved in Therapeutics Development | 36 | 45 |
Abivax SA | 36 | 1 |
AnGes MG Inc | 37 | 1 |
ANP Technologies Inc | 38 | 1 |
Arno Therapeutics Inc | 39 | 1 |
BioCryst Pharmaceuticals Inc | 40 | 1 |
BioFactura Inc | 41 | 1 |
Celgene Corp | 42 | 1 |
Emergent BioSolutions Inc | 43 | 1 |
Enyo Pharma SAS | 44 | 1 |
Etubics Corp | 45 | 1 |
GeoVax Labs Inc | 46 | 1 |
Gilead Sciences Inc | 47 | 1 |
GlaxoSmithKline Plc | 48 | 1 |
Hemispherx Biopharma Inc | 49 | 1 |
Humabs BioMed SA | 50 | 1 |
Immune Response BioPharma Inc | 51 | 1 |
Immunovaccine Inc | 52 | 1 |
Inovio Pharmaceuticals Inc | 53 | 1 |
Integrated BioTherapeutics Inc | 54 | 1 |
Johnson &Johnson | 55 | 1 |
Kineta Inc | 56 | 1 |
Kymab Ltd | 57 | 1 |
Medicago Inc | 58 | 1 |
Merck &Co Inc | 59 | 1 |
Microbiotix Inc | 60 | 1 |
Micropharm Ltd | 61 | 1 |
NanoViricides Inc | 62 | 1 |
Navigen Pharmaceuticals, Inc. | 63 | 1 |
Novavax Inc | 64 | 1 |
Peregrine Pharmaceuticals Inc | 65 | 1 |
Phelix Therapeutics LLC | 66 | 1 |
PlantForm Corp | 67 | 1 |
Profectus BioSciences Inc | 68 | 1 |
RedHill Biopharma Ltd | 69 | 1 |
Regeneron Pharmaceuticals Inc | 70 | 1 |
Rodos BioTarget GmbH | 71 | 1 |
SignPath Pharma Inc | 72 | 1 |
Sirnaomics Inc | 73 | 1 |
Soligenix Inc | 74 | 1 |
Taiga Biotechnologies Inc | 75 | 1 |
Tamir Biotechnology Inc | 76 | 1 |
TGV-Laboratories | 77 | 1 |
Toyama Chemical Co Ltd | 78 | 1 |
Vaxart Inc | 79 | 1 |
XBiotech Inc | 80 | 1 |
Ebolavirus Infections (Ebola Hemorrhagic Fever) Therapeutics Assessment | 81 | 10 |
Assessment by Monotherapy Products | 81 | 1 |
Assessment by Combination Products | 82 | 1 |
Assessment by Target | 83 | 2 |
Assessment by Mechanism of Action | 85 | 2 |
Assessment by Route of Administration | 87 | 2 |
Assessment by Molecule Type | 89 | 2 |
Drug Profiles | 91 | 159 |
(Ebola + Marburg) (monovalent) vaccine Drug Profile | 91 | 2 |
(Ebola + Marburg) (trivalent) vaccine Drug Profile | 93 | 2 |
(Ebola + Marburg) vaccine Drug Profile | 95 | 1 |
(Ebola [Sudan, Zaire] + Marburg) vaccine Drug Profile | 96 | 4 |
(Ebola [Sudan] + Marburg) vaccine Drug Profile | 100 | 1 |
(Ebola [Zaire] + rabies) (bivalent) vaccine Drug Profile | 101 | 1 |
(REGN-3470 + REGN-3471 + REGN-3479) Drug Profile | 102 | 1 |
1-E703 Drug Profile | 103 | 1 |
ABX-544 Drug Profile | 104 | 1 |
ANP-015 Drug Profile | 105 | 1 |
Antibodies for Ebola and Marburg Viral Infections Drug Profile | 106 | 1 |
Antibody for Ebola Viral Infection Drug Profile | 107 | 1 |
AR-12 Drug Profile | 108 | 3 |
ARD-5 Drug Profile | 111 | 1 |
bavituximab Drug Profile | 112 | 15 |
CC-11050 Drug Profile | 127 | 1 |
cosfroviximab + larcaviximab + porgaviximab Drug Profile | 128 | 3 |
DEF-201 Drug Profile | 131 | 2 |
DLANA-14 Drug Profile | 133 | 1 |
DPX-Ebola Drug Profile | 134 | 1 |
Drug for Ebola Virus Infection Drug Profile | 135 | 1 |
Drugs to Inhibit Cathepsin B for Ebola Viral Infections Drug Profile | 136 | 1 |
Ebola (virus like particle) vaccine Drug Profile | 137 | 1 |
Ebola [Zaire] (monovalent) vaccine Drug Profile | 138 | 2 |
Ebola [Zaire] vaccine Drug Profile | 140 | 5 |
Ebola [Zaire] vaccine Drug Profile | 145 | 1 |
Ebola [Zaire] vaccine Drug Profile | 146 | 1 |
Ebola [Zaire] vaccine Drug Profile | 147 | 2 |
Ebola [Zaire] vaccine Drug Profile | 149 | 2 |
Ebola [Zaire] vaccine Drug Profile | 151 | 1 |
Ebola [Zaire] vaccine Drug Profile | 152 | 1 |
Ebola vaccine Drug Profile | 153 | 1 |
Ebola vaccine Drug Profile | 154 | 1 |
Ebola vaccine Drug Profile | 155 | 1 |
Ebola vaccine Drug Profile | 156 | 1 |
Ebola vaccine Drug Profile | 157 | 1 |
Ebola vaccine Drug Profile | 158 | 1 |
Ebola vaccine Drug Profile | 159 | 1 |
EBOTAb Drug Profile | 160 | 1 |
favipiravir Drug Profile | 161 | 3 |
FBH-004 Drug Profile | 164 | 1 |
FDX-000 Drug Profile | 165 | 1 |
Fibrinoplate-S Drug Profile | 166 | 1 |
galidesivir Drug Profile | 167 | 3 |
Gene Therapy for Ebola Virus Infections Drug Profile | 170 | 1 |
GOVXE-301 Drug Profile | 171 | 1 |
GOVXE-302 Drug Profile | 172 | 1 |
GreEMTri Drug Profile | 173 | 1 |
GS-5734 Drug Profile | 174 | 1 |
imatinib mesylate Drug Profile | 175 | 1 |
ImmunoRx Drug Profile | 176 | 1 |
INO-4212 Drug Profile | 177 | 2 |
interferon alfa-n3 Drug Profile | 179 | 4 |
IRE-101 Drug Profile | 183 | 1 |
KIN-1400 Drug Profile | 184 | 2 |
KV-7005 Drug Profile | 186 | 1 |
Lalistat Drug Profile | 187 | 1 |
Lipocurc Drug Profile | 188 | 2 |
mAb-100 Drug Profile | 190 | 1 |
mAb-114 Drug Profile | 191 | 1 |
MB-003 Drug Profile | 192 | 1 |
MBX-2806 Drug Profile | 193 | 1 |
MIL-77 Drug Profile | 194 | 1 |
Monoclonal Antibodies 1 for Ebolavirus Infections Drug Profile | 195 | 1 |
Monoclonal Antibodies 2 for Ebolavirus Infections Drug Profile | 196 | 1 |
Monoclonal Antibodies for Ebola and Marburg Infections Drug Profile | 197 | 1 |
Monoclonal Antibodies for Ebola Viral Infections Drug Profile | 198 | 1 |
Monoclonal Antibodies for Viral Infections Drug Profile | 199 | 1 |
Monoclonal Antibodies to Inhibit Glycoproteins for Ebola Viral Infections Drug Profile | 200 | 1 |
MonoClonal Antibody for Ebola and Marburg Infections Drug Profile | 201 | 1 |
Monoclonal Antibody for Ebola Viral Infections Drug Profile | 202 | 1 |
Monoclonal Antibody for Ebola Viral Infections Drug Profile | 203 | 1 |
Monoclonal Antibody to Inhibit Glycoprotein for Ebola and Marburg Infections Drug Profile | 204 | 1 |
MV-4 Drug Profile | 205 | 1 |
NCK-8 Drug Profile | 206 | 1 |
nilotinib Drug Profile | 207 | 1 |
OS-2966 Drug Profile | 208 | 2 |
ranpirnase Drug Profile | 210 | 3 |
RBT-05 Drug Profile | 213 | 1 |
Recombinant Protein VSF for Viral Infections Drug Profile | 214 | 1 |
rintatolimod Drug Profile | 215 | 9 |
RKP-00156 Drug Profile | 224 | 1 |
SAB-139 Drug Profile | 225 | 1 |
Small Molecule 1 for Ebola Viral Infection Drug Profile | 226 | 1 |
Small Molecule 2 for Ebola Viral Infection Drug Profile | 227 | 1 |
Small Molecule for Ebola Viral Infection Drug Profile | 228 | 1 |
Small Molecules for Ebola and Marburg Infections Drug Profile | 229 | 1 |
Small Molecules for Ebola and Marburg Infections Drug Profile | 230 | 1 |
Small Molecules for Ebola and Marburg Virus Infections Drug Profile | 231 | 1 |
Small Molecules for Ebola Viral Infections Drug Profile | 232 | 1 |
Small Molecules for Ebola Virus Infections Drug Profile | 233 | 1 |
Small Molecules for Ebolavirus Infections Drug Profile | 234 | 1 |
Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections Drug Profile | 235 | 1 |
Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus Drug Profile | 236 | 1 |
Small Molecules to Inhibit NPC1 for Ebola Viral Infections Drug Profile | 237 | 1 |
Small Molecules to Inhibit Nucleoprotein for Ebola Virus Infections Drug Profile | 238 | 1 |
Small Molecules to Inhibit VP40 for Ebola and Marburg Viral Infections Drug Profile | 239 | 1 |
STP-802 Drug Profile | 240 | 1 |
Synthetic Peptides for Ebola Virus Drug Profile | 241 | 1 |
TMR-004 Drug Profile | 242 | 1 |
UV-4B Drug Profile | 243 | 1 |
V-920 Drug Profile | 244 | 5 |
ZMAb Drug Profile | 249 | 1 |
Ebolavirus Infections (Ebola Hemorrhagic Fever) Dormant Projects | 250 | 5 |
Ebolavirus Infections (Ebola Hemorrhagic Fever) Discontinued Products | 255 | 1 |
Ebolavirus Infections (Ebola Hemorrhagic Fever) Product Development Milestones | 256 | 16 |
Featured News &Press Releases | 256 | 1 |
Oct 18, 2016: Canadian Ebola vaccine enters new trial phase | 256 | 1 |
Sep 12, 2016: Johnson &Johnson Announces World Health Organization will Review Ebola Vaccine Regimen for Emergency Use Assessment and Listing (EUAL) | 257 | 2 |
Sep 07, 2016: BioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in a Non-Human Primate Model | 259 | 1 |
Aug 11, 2016: Inovio Pharmaceuticals Expands Positive Phase I Ebola Vaccine Trial to Identify Most Optimal Immunization Regimen | 259 | 1 |
Jul 28, 2016: Ranpirnase Shows Antiviral Effect Against Ebola | 260 | 1 |
Jul 25, 2016: Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920) | 261 | 1 |
Jul 18, 2016: Soligenix Announces Presentation of Positive Preliminary Results of a Heat Stable Ebola Vaccine Formulation | 262 | 1 |
Jul 05, 2016: PREVAIL treatment trial for men with persistent Ebola viral RNA in semen opens in Liberia | 263 | 1 |
Jun 14, 2016: The anti-influenza drug Avigan Tablet selected as one of the supplies to be procured with the Japanese governments emergency grant aid for countering the Ebola Virus Disease in Guinea | 264 | 1 |
Jun 01, 2016: GeoVax Ebola Vaccine Protects Non-Human Primates Against Lethal Challenge | 265 | 1 |
May 04, 2016: Inovio Pharmaceuticals Showcases its Broad Pipeline of DNA-based Immunotherapies, Vaccines and dMAbs at the American Society of Gene &Cell Therapy | 266 | 1 |
May 02, 2016: Ebola vaccine: Promising phase I trials | 267 | 1 |
Apr 25, 2016: NewLink Genetics Awarded $21.6 Million Contract Option by BARDA for Ebola Vaccine Development | 268 | 1 |
Apr 19, 2016: Global Public-Private Partnership Announces Publication of Positive Phase 1 Data for Ebola Vaccine Regimen in JAMA | 269 | 2 |
Apr 15, 2016: NewLink Genetics Receives $2.8 Million Award from DTRA to Develop a Multivalent Filovirus Vaccine | 271 | 1 |
Appendix | 272 | 2 |
Methodology | 272 | 1 |
Coverage | 272 | 1 |
Secondary Research | 272 | 1 |
Primary Research | 272 | 1 |
Expert Panel Validation | 272 | 1 |
Contact Us | 272 | 1 |
Disclaimer | 273 | 1 |